Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Prior treatment

• More than one line of prior chemotherapy before current/planned triplet therapy
• Prior or whole-pelvis or wide-field radiotherapy
• History of or concurrent ocular disorders
• Not appropriate for bevacizumab treatment
• Prior hypersensitivity to monoclonal antibodies
• Received prior MIRV or other FRα-targeting agents

Other illness

• PD (progressive disease) while on or following platinum-based therapy
• History of other malignancy within 3 years prior to signing study consent

Other

• Endometrioid, clear cell, mucinous, or sarconmatous histology; mixed tumors containing any of the above or low grade/borderline ovarian tumor
• \> Grade 1 peripheral neuropathy
• Grade 4 thromboembolic events
• Requiring use of folate-containing supplements
• Pregnant or breatfeeding women
• Untreated or symptomatic central nervous system metastases

• Adult women \>/=18 years old
• Confirmed diagnosis of high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer
• Confirmed high FRα expression by regulatory-agency approved Ventana FOLR1 (FOLR1-2.1)
• Relapsed disease after frontline (first-line) platinum-based chemotherapy and must be plantinum-sensitive
• Willing and able to sign the informed consent form (ICF) and adhere to protocol requirements
• Negative pregnancy test and willing to use highly effective contraceptive method(s) while on study medication and for at least 7 months after the last dose of MIRV and 6 months after the last dose of bevacizumab